Amneal Pharmaceuticals, INC

Amneal Pharmaceuticals announced the completion of its acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader.

Amneal Pharmaceuticals announced that its stockholders have approved the acquisition of Kashiv BioSciences, LLC, with the transaction expected to close in the second half of 2026.

Amneal Pharmaceuticals announced strong second quarter 2026 results, exceeding expectations with a 10% revenue increase and raising full-year guidance, driven by growth in specialty and affordable medicines.

Amneal Pharmaceuticals announced first quarter 2026 results with net revenue of $723 million, a 4% increase year-over-year, and affirmed its full-year 2026 guidance.

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $375 million in cash and stock, plus potential milestone and royalty payments, aiming to bolster its global biosimilar capabilities and reported strong preliminary Q1 2026 results.

Amneal Pharmaceuticals announced strong fourth quarter and full year 2025 financial results, meeting or exceeding all guidance metrics and projecting continued growth for 2026.

Amneal Pharmaceuticals, Inc. announced a significant increase in net revenue and operating income for the second quarter of 2026, driven by growth across its key segments.

Amneal Pharmaceuticals reports a significant increase in net income and gross profit for Q1 2026, driven by robust performance in its Specialty segment and improved manufacturing efficiencies.

Amneal Pharmaceuticals, Inc. reported a return to net income in Q3 2025, driven by revenue growth across all segments and strategic debt refinancing, despite an impairment charge and increased operating expenses.

Amneal Pharmaceuticals Inc. reported significant net income and EPS growth in Q2 2025, driven by new product launches and strategic segment performance, alongside major debt refinancing.

Amneal Pharmaceuticals' Q1 2025 revenue increased by 5.5% year-over-year, driven by growth in Affordable Medicines, AvKARE, and Specialty segments.

Amneal Pharmaceuticals saw a 13.3% increase in revenue year-over-year in Q3 2024, driven by growth in generics, specialty, and AvKARE segments.

Amneal Pharmaceuticals achieved significant revenue growth in 2025, driven by new product launches and biosimilar approvals, despite ongoing competitive and regulatory challenges.

Amneal Pharmaceuticals' 2024 10-K filing reveals a year of mixed financial performance, marked by strategic collaborations and a significant opioid litigation settlement.

Amneal Pharmaceuticals' 2023 10-K filing provides a comprehensive overview of its capital stock, business segments, financial performance, and risk factors, highlighting a year of strategic reorganization and operational expansion.

Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, Inc., sold 146,403 shares of common stock on August 12, 2026 for $17.51 per share.

Tushar Bhikhubhai Patel, a 10% owner of Amneal Pharmaceuticals, Inc., received 12,763,469 shares of common stock on August 10, 2026.

Chintu Patel, Co-CEO and a Director of Amneal Pharmaceuticals, Inc., received 6,381,734 shares of common stock on August 10, 2026.

Gautam Patel, a Director of Amneal Pharmaceuticals, Inc., received 283,632 shares of common stock on August 10, 2026.

Chirag K. Patel, President & Co-CEO and a Director of Amneal Pharmaceuticals, Inc., received 6,381,734 shares of common stock on August 10, 2026.

Amneal Pharmaceuticals Director Deborah M. Autor reported a sale of 34,819 shares of Class A Common Stock on May 11, 2026, for a weighted average price of $12.94 per share.

Amneal Pharmaceuticals, Inc. reported robust financial and operational performance in 2025, driven by new product launches, double-digit revenue growth in key segments, and significant debt refinancing.

Amneal Pharmaceuticals has filed definitive additional proxy soliciting materials with the SEC.

Amneal Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on May 6, 2025, to vote on director elections, executive compensation, say-on-pay frequency, and auditor ratification.

Amneal Pharmaceuticals has filed a definitive proxy statement with the SEC.

Amneal Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on May 2, 2024, to vote on director elections, executive compensation, and the ratification of its independent auditor.

Tushar Patel reports increased beneficial ownership of Amneal Pharmaceuticals Class A Common Stock following the company's acquisition of Kashiv BioSciences.

Chirag Patel has increased his beneficial ownership in Amneal Pharmaceuticals, Inc. to 8.4% following the company's acquisition of Kashiv BioSciences.

Chintu Patel's Schedule 13D filing details his increased beneficial ownership of Amneal Pharmaceuticals Class A Common Stock following the company's acquisition of Kashiv BioSciences.

Dipan Patel's trusts sold nearly 7 million shares of Amneal Pharmaceuticals Class A Common Stock, reducing beneficial ownership to 5.4%.

Chintu Patel, a significant shareholder of Amneal Pharmaceuticals, Inc., has pledged over 13.2 million Class A Common Stock shares as collateral for a margin loan agreement with Citibank, N.A.

A trust controlled by Amneal Pharmaceuticals' significant shareholder, Dipan Patel, has pledged 3,050,000 Class A Common Stock shares as collateral for a $10 million loan from Enterprise Bank & Trust.

The Vanguard Group reported 0% beneficial ownership of Amneal Pharmaceuticals Inc. following an internal realignment, with subsidiaries now reporting separately.

Akram Mahesh has reported a beneficial ownership of 6.56% of Amneal Pharmaceuticals, Inc.'s Class A Common Stock as of March 31, 2025, through trusts managed by his wholly-owned Tattva Fiduciary Company.

The Vanguard Group has filed a Schedule 13G, reporting a 5.02% beneficial ownership stake in Amneal Pharmaceuticals Inc., totaling 15,762,727 shares of common stock.

UBS Group AG has filed an amended Schedule 13G for Amneal Pharmaceuticals, Inc., reporting zero beneficial ownership of Class A Common Stock as of December 31, 2024, following its acquisition of Credit Suisse Group AG.